← Back

SIGA Technologies Inc

3.48-52.2%1Y · USD

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market in the United States. Its lead product is TPOXX, an antiviral drug for treating human smallpox disease caused by the variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

Price · split & dividend adjusted
News & notes moving SIGA
United States
SIGA▼

SIGA Tech Profits Drop 65% but Cash and Special Payouts Remain

SIGA Technologies reported a 65% drop in net income for the second quarter, yet the company remained profitable, paid a special dividend, and completed its last major government contract. Product sales fell to $37.9 million from $79.1 million in the quarter, and total revenue slid to $41 million from $81.1 million, while net income dropped to $12.5 million from $35.5 million. The quarter included $37 million in TPOXX sales, with $24 million of IV TPOXX delivered to the US strategic national stockpile and $13 million of oral TPOXX sold to two international buyers. CEO Diem Nguyen highlighted deliveries across the US, Europe, and Asia-Pacific, noting the completion of the last procurement order under the 19C contract. The company also paid a special cash dividend of $0.6 per share in April, and trades at a forward P/E of just 2.99 as of September 4.
SIGA ▼
SIGA · Capital · Negative Net income dropped 65% and product sales fell sharply, though special dividend and contract completion noted.
Read original ↗
Insider Monkey·31dRead more →
United States
SIGA▲

SIGA targets FDA submission in H1 2027 while pursuing a new multiyear U.S. procurement contract

SIGA Technologies reported second-quarter product-related revenue of $38 million, including the final delivery under its existing U.S. contract, and is targeting an FDA submission for its post-exposure prophylaxis program in the first half of 2027. The $38 million consisted of $24 million of IV TPOXX delivered to the U.S. Strategic National Stockpile and $13 million of oral TPOXX delivered to two international customers. CEO Diem Nguyen said the company is actively engaging with the U.S. government on a new multiyear procurement contract, though progress has been slower than in the past due to changes within the Department of Health and Human Services. Internationally, SIGA is working with Hikma to expand TPOXX across the MENA region, with SIGA serving as the exclusive manufacturer and supplier. For the six months ended June 30, 2026, product-related revenues were $41 million, net income was $9 million, and the company held $118 million in cash with no debt.
SIGA ▲HIK.LSE ▲
SIGA · Demand · Positive Reports Q2 product revenue of $38M and targets FDA submission in H1 2027, with ongoing U.S. procurement contract discussions.
HIK.LSE · Demand · Positive Partnership with SIGA to expand TPOXX in MENA region, with SIGA as exclusive manufacturer and supplier.
Read original ↗
Seeking Alpha·61dRead more →
© 2026 MarketIVAsset